€8.65
Your prediction
Cresud S.A.C.I.F. y A. ADR Stock
Pros and Cons of Cresud S.A.C.I.F. y A. ADR in the next few years
Pros
Cons
Performance of Cresud S.A.C.I.F. y A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cresud S.A.C.I.F. y A. ADR | 0.580% | 0.000% | 8.805% | 50.435% | 2.976% | 84.043% | 3.861% |
| Sonae S.A. | -0.320% | - | - | - | - | - | - |
| Tallinna Kaubamaja Eo 0,6 | -4.230% | -0.834% | -8.733% | -0.627% | -1.553% | 2.589% | - |
| Apollo Medical Holdings, Inc. | -1.160% | -2.299% | -5.556% | 4.294% | -5.028% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.At first glance, CRESY's financials appear quite intriguing. Seeing a company within the Food & Drug Retailing industry with such an extensive asset base is not a frequent occurrence. Total assets have been substantially rising over the past three years. However, it is noteworthy that liabilities have been increasing in sync, which warrants further examination.
Growing Total Assets: Over the past three years, CRESY's total assets have been increasing remarkably, almost tripling from the 2021 figures to the 2023 figures. This speaks volumes about the company's expansion endeavours, signalling a proactive strategy to boost growth.
Significant Increase in Total Revenue: CRESY's total revenue has almost quadrupled during 2021-2023. This could indicate improvements in sales operations, increased consumer demand, or effective marketing strategies.